<DOC>
	<DOC>NCT02300532</DOC>
	<brief_summary>Post-marketing surveillance to investigate the clinical safety and effectiveness in patients of all implantation of Gliadel with malignant glioma in the actual medical setting.</brief_summary>
	<brief_title>Post-Marketing Surveillance of Gliadel 7.7mg Implant (All-case Observational Study)</brief_title>
	<detailed_description />
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<criteria>Inclusion criteria: Allpatient of Gliadel implantation Exclusion criteria:</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Malignant Glioma</keyword>
	<keyword>Glioblastoma Multiforme</keyword>
</DOC>